Want to join the conversation?
$MSI said that its 2Q16 Product sales fell 8% to $801MM vs. 2Q15. The majority of the decline was due to weakness in Latin America, parts of Europe and China. Product operating income was $176MM or 22% of sales, up 170 BP vs. last year, driven by steady margins and a lower cost structure. Backlog at quarter-end for this segment was $1.3Bil.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)